Results 41 to 50 of about 122,678 (147)

SARS-CoV-2 convalescence and hybrid immunity elicits mucosal immune responsesResearch in context

EBioMedicine, 2023
Summary: Background: Mucosal antibodies play a key role in the protection against SARS-CoV-2 infection in the upper respiratory tract, and potentially in limiting virus replication and therefore onward transmission. While systemic immunity to SARS-CoV-2
Olha Puhach, Mathilde Bellon, Kenneth Adea, Meriem Bekliz, Krisztina Hosszu-Fellous, Pascale Sattonnet, Nicolas Hulo, Laurent Kaiser, Isabella Eckerle, Benjamin Meyer   +9 more
doaj   +1 more source

Infectivity-enhancing antibodies against SARS-CoV-2

Uirusu, 2021
Antibodies against the receptor binding domain of the spike protein of SARS-CoV-2 play an important role in preventing infection as neutralizing antibodies. However, antibodies that recognize a specific site on the N-terminal domain of the spike protein induce an open domain of receptor binding that increases the binding of ACE2 and enhances the ...
openaire   +2 more sources

Dynamics of antibodies to SARS‐CoV‐2 in convalescent plasma donors

Clinical & Translational Immunology, 2021
Objectives Characterisation of the human antibody response to SARS‐CoV‐2 infection is vital for serosurveillance purposes and for treatment options such as transfusion with convalescent plasma or immunoglobulin products derived from convalescent plasma ...
Maurice Steenhuis, Gerard vanMierlo, Ninotska IL Derksen, Pleuni Ooijevaar‐de Heer, Simone Kruithof, Floris L Loeff, Lea C Berkhout, Federica Linty, Chantal Reusken, Johan Reimerink, Boris Hogema, Hans Zaaijer, Leo van deWatering, Francis Swaneveld, Marit J vanGils, Berend Jan Bosch, S Marieke vanHam, Anja tenBrinke, Gestur Vidarsson, Ellen C van derSchoot, Theo Rispens   +20 more
doaj   +1 more source

Nebulized mRNA‐Encoded Antibodies Protect Hamsters from SARS‐CoV‐2 Infection

Advanced Science, 2022
Despite the success of severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) vaccines, there remains a clear need for new classes of preventatives for respiratory viral infections due to vaccine hesitancy, lack of sterilizing immunity, and for at ...
Daryll Vanover, Chiara Zurla, Hannah E. Peck, Nichole Orr‐Burks, Jae Yeon Joo, Jackelyn Murray, Nathan Holladay, Ryan A. Hobbs, Younghun Jung, Lorena C. S. Chaves, Laura Rotolo, Aaron W. Lifland, Alicia K. Olivier, Dapeng Li, Kevin O. Saunders, Gregory D. Sempowski, James E. Crowe Jr., Barton F. Haynes, Eric R. Lafontaine, Robert J. Hogan, Philip J. Santangelo   +20 more
doaj   +1 more source

Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition

Cell Reports, 2021
Summary: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineages that are more transmissible and resistant to currently approved antibody therapies poses a considerable challenge to the clinical treatment of coronavirus ...
Kevin J. Kramer, Nicole V. Johnson, Andrea R. Shiakolas, Naveenchandra Suryadevara, Sivakumar Periasamy, Nagarajan Raju, Jazmean K. Williams, Daniel Wrapp, Seth J. Zost, Lauren M. Walker, Steven C. Wall, Clinton M. Holt, Ching-Lin Hsieh, Rachel E. Sutton, Ariana Paulo, Rachel S. Nargi, Edgar Davidson, Benjamin J. Doranz, James E. Crowe, Jr., Alexander Bukreyev, Robert H. Carnahan, Jason S. McLellan, Ivelin S. Georgiev   +22 more
doaj   +1 more source

SARS-CoV-2 antibodies persist

Science, 2020
Coronavirus As the number of daily COVID-19 cases continues to mount worldwide, the nature of the humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains uncertain. Wajnberg et al. used a cohort of more than 30,000 infected individuals with mild to moderate COVID-19 symptoms to determine the robustness and ...
openaire   +1 more source

SARS-CoV-2-Neutralizing Antibodies

Vaccines
The COVID-19 pandemic, triggered by the SARS-CoV-2 virus, has profoundly and permanently affected many aspects of the world [...]
Yawen Liu, Jianhui Nie
openaire   +3 more sources

Dromedary camels as a natural source of neutralizing nanobodies against SARS-CoV-2

JCI Insight, 2021
The development of prophylactic and therapeutic agents for coronavirus disease 2019 (COVID-19) is a current global health priority. Here, we investigated the presence of cross-neutralizing antibodies against severe acute respiratory syndrome coronavirus ...
Lotfi Chouchane, Jean-Charles Grivel, Elmoubasher Abu Baker Abd Farag, Igor Pavlovski, Selma Maacha, Abbirami Sathappan, Hamad Eid Al-Romaihi, Sirin W.J. Abuaqel, Manar Mahmoud Ahmad Ata, Aouatef Ismail Chouchane, Sami Remadi, Najeeb Halabi, Arash Rafii, Mohammed H. Al-Thani, Nico Marr, Murugan Subramanian, Jingxuan Shan   +16 more
doaj   +1 more source

Detection of breastmilk antibodies targeting SARS-CoV-2 nucleocapsid, spike and receptor-binding-domain antigens

Emerging Microbes and Infections, 2020
A 40-year-old female was found to have strongly neutralizing SARS-CoV-2 breastmilk IgA and IgG antibodies reactive against multiple SARS-CoV-2 antigens at 2.5 months after documented infection with SARS-CoV-2.
D. M. Favara, M. L. Ceron-Gutierrez, G. W. Carnell, J. L. Heeney, P. Corrie, R. Doffinger   +5 more
doaj   +1 more source

Monoclonal antibodies lock down SARS-CoV-2 spike

Trends in Immunology, 2023
SARS-CoV-2 rapidly accumulated mutations in its immunodominant receptor-binding domain (RBD), rendering all clinically authorized monoclonal antibodies (mAbs) ineffective. Liu et al. unveil potent human mAbs that neutralize all tested SARS-CoV-2 variants by locking the Spike protein RBD in a downward conformation, thus inhibiting receptor engagement.
Huang, Hsiang-Chi, Angeletti, Davide
openaire   +2 more sources